|
Post by huh on Apr 1, 2014 17:26:50 GMT -5
MNKD up 134% after hours. Can you say short squeeze. Yesterday it was at $4 and now over $9 GL Wow. Congrats! Go BM, go BM.
|
|
|
Post by maxi on Apr 1, 2014 17:42:22 GMT -5
MNKD up 134% after hours. Can you say short squeeze. Yesterday it was at $4 and now over $9 GL THAT is SOOOOO freaking GREAT Mark! Huge congrats. I know that hold was a roller coaster!
|
|
|
Post by jacksrbtr on Apr 1, 2014 17:48:26 GMT -5
MNKD up 134% after hours. Can you say short squeeze. Yesterday it was at $4 and now over $9 GL Congratz!!! BM!!!!! Fantastic!
|
|
|
Post by huh on Apr 2, 2014 7:17:27 GMT -5
MNKD was halted for the entire day yesterday? Is that normal for these pending announcements?
|
|
|
Post by Herceg on Apr 2, 2014 9:30:01 GMT -5
MNKD was halted for the entire day yesterday? Is that normal for these pending announcements? I guess it depends on when the announcement is, I have seen them make announcements one night and open the next morning..........they are always good to short like today on MNKD............People always want to lock in profits although the new shorts usually enter at the same time..................however it always drifts lower if following the charts.......... JMO and BOL.......
|
|
|
Post by maxi on Apr 2, 2014 12:04:48 GMT -5
it did better than drift lower it fell from the nines to the low 7's.... Hate that I do not have an acct I can short in.
|
|
|
Post by maxi on Apr 2, 2014 12:32:13 GMT -5
Something else to consider on any biotech that gets the go ahead ..... The company then has to have the cash to put the product into production and cash to pay sales force (or expand sales force) etc. So altho I have not looked up MNKD cash reserves it is possible they will raise cash in the future which may give one an opportunity to enter at a lower price than here. Just because a company does a capital raise tho does not mean the price will fall dramatically. If investors believe the product has a lot of potential then they will just buy up the offer.... (all that FWIW)
|
|
|
Post by maxi on Apr 2, 2014 12:36:24 GMT -5
ATOS. this is pretty good news for ATOS. They still have to get the 510 approval thru but hiring this guy should prevent further episodes of the stock dying. They were at 5 a share when there was a series of mess ups by management. All of that is slowly being corrected... finance.yahoo.com/news/ben-r-chen-joins-atossa-123000638.html
|
|
|
Post by jacksrbtr on Apr 2, 2014 13:03:27 GMT -5
Something else to consider on any biotech that gets the go ahead ..... The company then has to have the cash to put the product into production and cash to pay sales force (or expand sales force) etc. So altho I have not looked up MNKD cash reserves it is possible they will raise cash in the future which may give one an opportunity to enter at a lower price than here. Just because a company does a capital raise tho does not mean the price will fall dramatically. If investors beleive the product has alot of potential then they will just buy up the offer.... (all that FWIW) Don't take this the wrong way Maxi, but I'm gonna ask you the same thing my Dad used to ask my Mom ALL the time: "What makes you so smart?" And he meant it...I think.
|
|
|
Post by huh on Apr 2, 2014 13:15:17 GMT -5
Something else to consider on any biotech that gets the go ahead ..... The company then has to have the cash to put the product into production and cash to pay sales force (or expand sales force) etc. So altho I have not looked up MNKD cash reserves it is possible they will raise cash in the future which may give one an opportunity to enter at a lower price than here. Just because a company does a capital raise tho does not mean the price will fall dramatically. If investors beleive the product has alot of potential then they will just buy up the offer.... (all that FWIW) Don't take this the wrong way Maxi, but I'm gonna ask you the same thing my Dad used to ask my Mom ALL the time: "What makes you so smart?" And he meant it...I think. LOL Maxi definitely has the smart post of the day. I was even thinking that when I read it. So many run from dilution, but sometimes it can be the best thing for a company - if they truly need the capital in order make more money. Many of those same people likely run TO many of the recent IPOs that really can't increase profits with an influx of cash and only use it to buy other companies in the same scenario, or simply pay the owners.
|
|
|
Post by huh on Apr 9, 2014 14:25:15 GMT -5
MNKD -- a step closer to getting approved by FDA. Anybody have any? GL Might be a little cautious of MNKD here ~7.07. Can't post a chart right now, but that's the target of a failed rising wedge from this week - could also produce a double-top. Wouldn't necessarily sell it, but it must hold 6.88 now worst case. I'll post a chart later (I'm LT bullish on it - but could pullback here)
|
|
|
Post by huh on Apr 9, 2014 19:37:02 GMT -5
MNKD -- a step closer to getting approved by FDA. Anybody have any? GL Might be a little cautious of MNKD here ~7.07. Can't post a chart right now, but that's the target of a failed rising wedge from this week - could also produce a double-top. Wouldn't necessarily sell it, but it must hold 6.88 now worst case. I'll post a chart later (I'm LT bullish on it - but could pullback here) The only reason I see to be cautious here is because those failed rising wedge upside targets (shown in white) usually result in ST tops - and many times it will make a slightly higher high (2-3%) before turning down. I've shown examples of these before in AMZN, NDX and it's very likely SPX is working on the same pattern now. The FIBs shown (red) are for the down move from the 04/02 high to the 04/07 low. That 04/07 low was a 50% FIB for that large jump from 03/31 low to 04/02 high. Seems this stock likes the 50% FIBs, and 7.01 is now the 50% FIB for the 04/02-04/07 down move. And you can see the obvious support at 6.88 (which is also a 61.8 FIB from the this morning's low to HOD). Like I said before, I'm long term bullish on this one. But if it loses the 6.88 support, or, more likely, hits 7.24-7.28 then loses 7.01, it could pull back for a bit. Only something to watch for. DISCLAIMER - Take it FWIW knowing that my track record with bios usually stinks.
|
|
|
Post by huh on Apr 15, 2014 12:15:38 GMT -5
MNKD now down 13.6% from that support break, and down 15.9% from that rising wedge upside target I posted about. Unfortunately it never got as high as 2% over that target (only 1.4%).
This 5.94/5.95 area is the 50% FIB retracement. If it were to close under 5.95, next support is ~5.45. (but remember, this stock seems to like those 50% retracements)
|
|
|
Post by maxi on Apr 15, 2014 12:30:43 GMT -5
CRDC may have reached a bottom. Up 5%+ today. But the close is what matters.....
|
|
|
Post by maxi on Apr 15, 2014 12:35:40 GMT -5
I bought 200 shares of HALO. 7.38 Citipoop has a target of 12 for it. OK I'm game ( or a sucker)..Hard to switch out of medical and biotech etc. Thanks to Jacks post from ITMS I have a downside target for bounce too. IBB is ratcheting up and down a lot here around 208.42
Oops now 211. maybe it will give it a break here. That would be nice...
|
|
|
Post by huh on Apr 15, 2014 22:33:43 GMT -5
Interesting post on bios from ST: afmarko99 "$ARIA Biotech historical trends. March/April buying times. stks.co/d0RQv " @vstn
|
|
|
Post by maxi on Apr 17, 2014 12:32:47 GMT -5
Back in ATHX yesterday at 2.59 A close over 2.80 would be excellent.
|
|
|
Post by novie08 on Apr 21, 2014 9:15:18 GMT -5
Wittle ASTM made a purchase, now +29%...but I'm STILL underwater. 31 am Aastrom Biosciences (halted) to acquire Sanofi's Cell Therapy and Regenerative Medicine Business (ASTM) : Co announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (:CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. •Carticel (autologous cultured chondrocytes) is an autologous chondrocyte implant (ACI) currently marketed in the United States for the treatment of articular cartilage defects. •Epicel (cultured epidermal autografts) is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area, and is marketed in countries around the world. •MACI (matrix-induced autologous chondrocyte implant) is a third-generation ACI product currently marketed in the European Union. Revenues of those three products were $44 million in 2013. And the bonus?: Thomson Reuters downgraded it on Fri.
|
|
|
Post by maxi on Apr 22, 2014 12:17:28 GMT -5
Contrary to the rest of the market SUMMER is when Bio's shine. Mainly because of all the conferences....
|
|
|
Post by maxi on Apr 22, 2014 13:24:21 GMT -5
I bought 200 shares of HALO. 7.38 Citipoop has a target of 12 for it. OK I'm game ( or a sucker)..Hard to switch out of medical and biotech etc. Thanks to Jacks post from ITMS I have a downside target for bounce too. IBB is ratcheting up and down a lot here around 208.42 Oops now 211. maybe it will give it a break here. That would be nice... Sold the 200 shares of HALO for 7.94.... 7.5% I should know better than to buy only 200 shares...lol... But I have a feeling CRDC is going to be a better place to be...
|
|